stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Free cash flow
Novo Nordisk A/S's free cash flow for fiscal 2025 was $4.4B, down 56.5% from $10.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $7.6B. Over the past ten years it has ranged from $4.4B (fiscal 2025) to $10.2B (fiscal 2023) — the current reading is the lowest in ten years. Novo Nordisk A/S ranks 12th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $4.4B | (56.55%) |
| FY2024 | $10.1B | (0.64%) |
| FY2023 | $10.2B | 11.94% |
| FY2022 | $9.1B | 19.88% |
| FY2021 | $7.6B | 65.51% |
| FY2020 | $4.6B | (14.12%) |
| FY2019 | $5.3B | 8.19% |
| FY2018 | $4.9B | (0.30%) |
| FY2017 | $4.9B | (16.98%) |
| FY2016 | $6.0B | 25.41% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $6.6B | 249.11% |
| Mar 2026 | $1.9B | — |
| Dec 2025 | −$5.8B | — |
| Sep 2025 | $5.0B | 29.28% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| NVS Novartis AG compare | $14.1B |
| GILD Gilead Sciences, Inc. compare | $13.8B |
| PFE Pfizer Inc. compare | $11.8B |
| AMGN Amgen Inc. compare | $9.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| GSK GSK PLC Sponsored ADR compare | $8.8B |
| NVO Novo Nordisk A/S | $7.6B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement